AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

Prostate Cancer Clinical Trial

Official title:

Angelica Herbal Supplement AGN-CognI.Q Acute Dose Safety and Pharmacokinetics (PK) Dose-Response in Prostate Cancer Patients (PK Dose Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05375539
• Other study ID #: PSCI-21-173
• Status: Recruiting
• Phase: Phase 1
• Start date: May 2, 2023
• Est. completion date: May 30, 2025

Study information

• Verified date: June 2024
• Source: Milton S. Hershey Medical Center
• Contact: Junxuan Lu, Ph.D
• Phone: 717-531-8964
• Email: junxuanlu[@]pennstatehealth.psu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to obtain acute dose safety and pharmacokinetics/pharmacodynamics (PK/PD) data in a dose-response trial in prostate cancer patients.

Description:

The long-term goal of the study is to conduct human clinical trials to test Angelica gigas Nakai (AGN) root alcoholic extract herbal supplement product (AGN-CognI.Q, or CognI.QTM, made with INM®176 proprietary ingredient, Quality of Life Laboratories, Purchase, NY) as a safe and potential efficacious modality for prostate cancer interception akin to secondary prevention to delay hormonal therapy or avoid it entirely after patients have developed recurrent disease following their standard of care (SOC) surgery and radiation curative treatment. The acute dose safety and pharmacokinetics (PK) and pharmacodynamics (PD) information in the target patient population from the current proposed acute PK dose-response trial will inform the optimal design and execution of the longer-term safety and efficacy (phase I/II) trials.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: May 30, 2025
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. Willingness and ability to give informed consent.

2. Agree to comply with all study procedures and attend all study visits to the best of their ability.

3. Male with age >=40 years.

4. History of prostate cancer diagnosis. Subjects with history of neuroendocrine or small cell prostate cancer will be excluded. Subjects are eligible if meet one or more of the below criteria:

1. Patients treated forprostate cancer and no detectable disease on imaging and clinical determination are eligible for enrollment, regardless of risk category.

2. Patients in the low-risk and favorable intermediate-risk groups who are not currently receiving any treatment or have declined any treatment.

5. Not on concurrent androgen deprivation therapy.

6. ECOG performance status 0-2.

7. Life expectancy of greater than 12 months.

8. Subjects must have normal liver and kidney function as defined below:

• a) total bilirubin within normal institutional limits,

• b) AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal,

• c) Creatinine within 1.5 ULN of institutional limits OR creatinine clearance > 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.

• d) Adequate bone marrow function (Hgb = 9.0 g/dL, Platelets = 100 x 109/L, absolute neutrophil count (ANC) of = 1.5 x 109/L), except for subjects with a history of chronic benign neutropenia, where an ANC of = 1.0 x 109/L are eligible.

9. Subjects must agree to use two medically accepted method of contraception and must agree to continue use this method while on the trial and through at least one week after the last dose of study drug. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD) known to have a failure rate of less than 1% per year, or steroidal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) withdrawal, spermicides only, or lactational amenorrhea are not acceptable methods of contraception.

10. Subjects must stop the CYP3A4 and CYP2C19 strong inhibitors or inducers 2 weeks prior to the start of the study and during the study.

11. Subjects currently taking herbal supplements containing AGN extract, including CognI.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin must discontinue these or any other supplements containing these products 4 weeks prior to starting study drug.

Exclusion Criteria:

1. Subjects with distant metastatic cancer. Node positive prostate cancer patients are allowed after completion of treatment.

2. Subjects who are receiving chemotherapy, or oral TKI, or immunotherapy (checkpoint inhibitor).

3. Subjects who are receiving any other investigational agents.

4. Uncontrolled intercurrent illness that would limit compliance with study requirements.

5. All vulnerable patient populations.

6. History of New York Heart Association Class III or IV heart failure, history of a myocardial infarction within 6 months, any uncontrolled cardiac arrhythmia, or any other cardiac related problem that would be considered a contraindication for participation in the opinion of the treating physician.

7. Use of androgen deprivation therapy (ADT) or anti-androgen therapy including LHRH agonist, antagonist, GNRH analogs, and antiandrogens.

8. Subjects who are taking Warfarin/Coumadin.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• AGN-CognI.Q
Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.

Locations

Country	Name	City	State
United States	Penn State Cancer Institute	Hershey	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Milton S. Hershey Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Electrocardiography (EKG) QTC Interval	Cardiac safety measured by EKG QT Interval at baseline, at 5 hours (+/-60mins) and 24 h (+/-2hrs) after study drug treatment every study visit (usually weekly) up to 5 weeks	5-6 weeks
Primary	Safety blood lab tests	CBC diff for hematological safety and CMP for liver and kidney safety at baseline and 24 +/- 2 h after dose and before the next dose level (the latter also serves as baseline for the next dose).	5-6 weeks
Secondary	Peak Plasma Concentration (Cmax)	PK metrics of decursin (D) and its isomer decursinol angelate (DA) and their metabolite decursinol (DOH) will be measured in blood collected at pre-each dose baseline (0 h labs= baseline), 2h (+/- 30 mins), 3h (+/- 30 mins), 4h (+/- 30 mins), 5h (+/- 30 mins), 6h (+/-30mins), 7h (+/- 30 mins), and 24 h (+/-2hrs) to estimate Peak Plasma Concentration (Cmax).	4-6 weeks
Secondary	Plasma Concentration versus time curve (AUC)	PK metrics of decursin (D) and its isomer decursinol angelate (DA) and their metabolite decursinol (DOH) will be measured in blood collected at pre-each dose baseline (0 h labs= baseline), 2h (+/- 30 mins), 4h (+/- 30 mins), 6h (+/-30mins) and 24 h (+/-2hrs) to estimate Area under the Plasma Concentration versus time curve (AUC).	4-6 weeks